UroGen Pharma Ltd.: CFO Chris Degnan sold 2,202 shares

What happened Chris Degnan, chief financial officer, exercised or converted derivative securities for 4,483 shares on Oct 8, 2026 and sold 2,202 shares on the open market at $36.69 each for $80,791. The Form 4 lists an exercise/conversion (M) acquiring 4,483 shares and an exercise/conversion (M) disposing 4,483 shares at $0.00 (derivative).

Key details

• Transaction date: Oct 8, 2026; sale price: $36.69; sale proceeds: $80,791.
• Derivative transactions: 4,483 shares acquired (M) and 4,483 shares disposed at $0.00 (M).
• Shares owned after the transactions: not reported in the filing.
• Footnotes: F1 = each restricted stock unit (RSU) equals one ordinary share; F2 = shares sold to satisfy withholding tax obligations upon RSU settlement; F3 = 13,450 RSUs granted Oct 8, 2024 vesting in three equal annual installments from Oct 8, 2025.
• Filing date: Oct 9, 2026.

Why it may matter The filing indicates RSUs were settled and that 2,202 shares were sold to satisfy withholding tax obligations (share withholding rather than a cash tax payment). A filing does not show why the insider traded or why the company acted.